TOP BRD4 INHIBITION BY ABBV-744 IN CANCER RESEARCH STUDIES SECRETS

In Segment C, individuals will get ABBV-744 and oral navitoclax. In Phase D, individuals will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually condition progression or maybe the individuals are not able to tolerate the study drugs.All round, our existing work highlights the potential utilization of ARV-825 in combin